How do cancer patients respond to treatment? TK1 as biomarker in cancer care can help clinicians make timely and decisions about ongoing treatment of every patient.
Measurement of proliferation, or progression and remission of tumor growth is in the drug discovery. AroCell TK 210 ELISA, opens the opportunity to monitor the efficacy and dose response of drug candidates in drug discovery.
Arocell TK 210 ELISA is a simple test designed for the determination of TK1 in human blood. It is easy to use, robust and requires no special instrumentation to perform.
Increased levels of TK1 in the blood can indicate active cell proliferation as a consequence of abnormal cell turnover and cell disruption triggered by for example drug and therapeutic agents.
An extensive list of published articles on applications, Thymidine Kinase 1 and use of AroCell TK 210 ELISA.
AroCell is participating in several clinical studies, both with partners and independently.